REVIEW – Statins Boost Abiraterone (Zytiga) Activity in Prostate Cancer

Another piece of information from the recent ASCO GU conference in San Francisco Researchers have found that adding statin drugs may prolong the sensitivity of abiraterone acetate (Zytiga) in men with castration-resistant prostate cancer (CRPC) To assess the effect of statins on abiraterone therapy, Dr Harshman, of the Lank Center for Genitourinary Oncology at Dana-Farber [...]

NICE Recommends Xtandi, but Not Zytiga in the Pre-Chemotherapy Stage of Advanced Prostate Cancer Treatment

NICE, which serves as a cost-effectiveness agency has said in a draft guidance that it supports the use of Xtandi (enzalutamide) in men whose prostate cancer has spread after the failure of first-line therapy (i.e. ADT), but for whom chemotherapy is not yet necessary. The agency found that Xtandi can delay the need for chemotherapy, [...]

Initial Gleason Score Does Not Impact Abiraterone (Zytiga) Benefit in Prostate Cancer

Clinical trials have shown that there is an overall survival and radiographic progression-free survival benefit derived from abiraterone acetate (Zytiga) in the treatment of men with metastatic castration resistant prostate cancer (mCRPC). A new retrospective study published online, ahead of print, shows this trend is true regardless of a man's Gleason score at diagnosis, despite [...]

On The Horizon – Tests That Can Inform Us If A Drug Will Work Before We Take The Drug

We have become very fortunate over the last 6 years because our arsenal of potential drugs to treat advanced, metastatic prostate cancer has grown. All of our new drugs extend life and most offer palliation of pain. As I have discussed in prior posts we are still in a quandary about how best to sequence [...]

Abiraterone Is Effective In Men Over 75 Years Who Are Chemotherapy-Naive And Have mCRPC

We know that Abiraterone (Zytiga) extends life, but we also know that its side effects can be harsh, especially in elderly men (men over 75 years). We also know that men with metastatic, castrate resistant prostate cancer (mCRPC) have a limited potential life expectancy. Given these facts, it is important to know if, despite being [...]

How We Know What Drugs Might Work In Combination With Each Other – Bringing The Next Big Breakthrough in Prostate Cancer Treatment

Many of the posts that I have written discussed the need for evaluating our current advanced prostate cancer drugs in both combinations and their sequencing. We have a number of new drugs, but we don’t understand how best to sequence them, or whether or not some drugs would do better and extend life by taking [...]

Metabolic Syndrome in Men with Castration-Resistant Prostate Cancer Treated with Abiraterone Affects Their Survival

Yesterday’s post was about the increased risks of developing diabetes faced by men who are on hormone therapy. This study, as well as most others about this topic has looked at the first levels of hormone therapy (ADT) using the traditional drugs like Zoladex, Trelstar, Firmagon, and Lupron. We know very little about the influence [...]

The Development of A Novel Blood Biomarker for Detecting AR-V7 and Resistance to Zytiga and Xtandi

At the current AUA Annual Meeting going on in New Orleans, there was a presentation given by Haitao Zhang and colleagues. They described their work developing a novel blood-based assay (test) for detecting androgen receptor (AR) splice variants in men with advanced prostate cancer. Their work relies on the premise that AR-V7 expression underlies resistance [...]

Predicting Who Will Have A Positive Result From Abiraterone (Zytiga) In Men With Metastatic Castrate Resistant Prostate Cancer

We have many new drugs to treat metastatic castrate resistant prostate cancer (mCRPC), but not all men have a positive result to each of the drug. Understanding who might obtain a positive result to a specific drug prior giving it will save both the individual man and society time and money. Understanding this it becomes [...]

Radiologic Progression Free Survival Might Predict Treatment Response and Survival

In a recent publication it was suggested that radiographic progression-free survival (rPFS) in men with metastatic castration-resistant prostate cancer (mCRPC) was highly consistent and highly associated with overall survival. This reproducible quantitative find could have implications for the interim measurement of treatment response in future studies, according to Dr. Michael J. Morris of Memorial Sloan [...]

Go to Top